IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era

Although Indoleamine 2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO), and aryl hydrocarbon receptor (AHR) are involved in cancer immune escape, their prognostic impact on diffuse large B-cell lymphoma (DLBCL) is unknown. To examine the prognostic impact of IDO, TDO, and AHR on patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiangli, Zang, Yuzhu, Li, Dujuan, Guo, Jianmin, Wang, Yacai, Lin, Yuqi, Wei, Zhenghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249864/
https://www.ncbi.nlm.nih.gov/pubmed/32481253
http://dx.doi.org/10.1097/MD.0000000000019883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249864/
https://www.ncbi.nlm.nih.gov/pubmed/32481253
http://dx.doi.org/10.1097/MD.0000000000019883

Ejemplares similares